Woodmont Investment Counsel’s VanEck Pharmaceutical ETF PPH Stock Holding History

Woodmont Investment Counsel’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-23,775	Closed	-$1.37M	–	503
2016 Q3	$1.37M	Buy	23,775 +2,400	+11%	+$144K	0.39%	76
2016 Q2	$1.25M	Buy	+21,375	New	+$1.25M	0.37%	79
2016 Q1	–	Sell	-1,000	Closed	-$65K	–	547
2015 Q4	$65K	Hold	1,000	–	–	0.02%	242
2015 Q3	$63K	Sell	1,000 -500	-33%	-$35.1K	0.02%	245
2015 Q2	$106K	Buy	+1,500	New	+$108K	0.03%	214

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Colrain Capital Boston, Massachusetts $295M AUM 82.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

SCM

Stuyvesant Capital Management Armonk, New York $41.1M AUM 17.11% 1-Year Est. Return

Woodmont Investment Counsel's PPH Position: Q4 2016 in Review

Woodmont Investment Counsel sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2016, closing a stake of 23,775 shares — an estimated $1.37M sold.

Woodmont Investment Counsel first reported a position in PPH in Q2 2015 and held it in 5 quarters. The position peaked at $1.37M in Q3 2016. 51 funds tracked by Wall St. Rank hold PPH as of Q4 2016.

Woodmont Investment Counsel reported no remaining VanEck Pharmaceutical ETF position as of Q4 2016 after selling out during the quarter.
Woodmont Investment Counsel sold 23,775 VanEck Pharmaceutical ETF shares in Q4 2016, an estimated $1.37M.
Woodmont Investment Counsel first reported a position in VanEck Pharmaceutical ETF in Q2 2015 and held it in 5 quarters.
Woodmont Investment Counsel's VanEck Pharmaceutical ETF position peaked at $1.37M in Q3 2016.
51 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2016.

Based on Woodmont Investment Counsel's 13F filing for Q4 2016, filed 13 Feb 2017.